Clinical trials: Apixaban
Atrial Fibrillation
Trial of Apixaban vs Warfarin in Reducing Rate of Cognitive Decline, Silent Cerebral Infarcts and Cerebral Microbleeds in Patients With Atrial Fibrillation
The investigators' central hypothesis is that in patients with atrial fibrillation, anticoagulation with Apixaban reduces the rate of decline in cognitive function, when compared to Warfarin.
- Trial name
- ARISTA (NCT03839355)
- Testing
- Apixaban, Warfarin
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Mayo Clinic
Bleeding
A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban
The purpose of this stuy is to evaluate the ability of Andexanet Alfa to reverse the anticoagulation effect of Apixaban.
- Trial name
- NCT02207725
- Testing
- Andexanet
- Where
- United States
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Portola Pharmaceuticals
Atrial Fibrillation
Study to Evaluate the Use of Direct Oral Anticoagulants in UK Clinical Practice For Patients With a First Stroke Attributable to Nonvalvular Atrial Fibrillation
National Institute of Health and Care Excellence (NICE) guidance recommends anticoagulation for stroke prevention in high risk patients with nonvalvular atrial fibrillation (AF).
- Trial name
- NCT05262322
- Testing
- Edoxaban, Apixaban, Rivaroxaban
- Where
- 8 sites in United Kingdom
- Volunteers
- 234 people
- Sponsor
- Daiichi Sankyo UK Ltd, a Daiichi Sankyo Company
Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia
Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia
This is an open-label randomized controlled trial which will enroll patients with S. aureus bacteremia who are already taking oral anticoagulant medications (apixaban, edoxaban, or rivaroxaban) for an approved indication (stroke…
- Conditions
- Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia, Staphylococcus Aureus Bloodstream Infection
- Trial name
- DABI-SNAP (NCT06650501)
- Testing
- Dabigatran, Apixaban, edoxaban
- Where
- 3 sites in Canada
- Volunteers
- 300 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Health
Bioequivalence Study of Apixaban 5 mg Film-Coated Tablet
This was an open-label, randomized, single-dose, two-period, two-sequence, cross-over study under fasting condition which included 24 healthy adult male and female subjects.
- Trial name
- NCT06817811
- Testing
- Apixaban 5 mg Film-Coated Tablet (produced by PT Dexa Medica), Eliquis® 5 mg film-coated tablet (Bristol-Myers Squibb Company, Puerto Rico, packed and released by Bristol-Myers Squibb S.r.l., Italy, imported by PT Pfizer Indonesia)
- Where
- Indonesia
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Dexa Medica Group
COVID-19
A Study of Anticoagulation Treatment Patterns and Outcomes of Participants Hospitalized With Coronavirus Disease 2019 (COVID-19) in Japan
The purpose of this study is to describe demographic and clinical characteristics of participants who are hospitalized due to coronavirus 2019 (COVID-19), treatment use for COVID-19 and COVID-19 symptoms, and composite outcomes…
- Trial name
- NCT04828772
- Where
- 2 sites in Japan
- Volunteers
- 9,282 people
- Sponsor
- Bristol-Myers Squibb
Atrial Fibrillation (AF)
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation
This study is researching an experimental drug called REGN7508 (called "study drug") and how it compares against another treatment called apixaban.
- Trial name
- ROXI-EVEREST (NCT07626411)
- Testing
- REGN7508, Apixaban
- Where
- 54 sites in United States, Canada and 1 more
- Volunteers
- 15,364 people
- Sponsor
- Regeneron Pharmaceuticals
Nephrotic Syndrome, Proteinuria
Pharmacokinetics of Apixaban in Nephrotic Syndrome
This study is to investigate the pharmacokinetics and pharmacodynamics of apixaban in nephrotic syndrome.
- Trial name
- NCT02599532
- Testing
- apixaban
- Where
- United States
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Renal Disease, End Stage, Anticoagulant-induced Bleeding
Safety and Efficacy of Apixaban in Severe Renal Impairment
Despite emergence of new anticoagulants over the last few years, patients with advanced chronic kidney disease still have limited options and are usually managed with warfarin after venous thromboembolism or diagnosis of atrial…
- Trial name
- NCT03399305
- Where
- United States
- Sponsor
- Albert Einstein College of Medicine
Venous Thrombosis, Pulmonary Embolism
BMS-562247 in Subjects Undergoing Elective Total Knee Replacement Surgery
The purpose of this study is to learn if BMS-562247 can prevent blood clots in the legs and lungs in men and women following unilateral total knee replacement surgery. The safety of this treatment will also be studied.
- Trial name
- NCT00097357
- Testing
- Apixaban, Enoxaparin, Warfarin
- Where
- 147 sites in United States, Argentina and 7 more
- Volunteers
- 1,238 people
- Sponsor
- Bristol-Myers Squibb
Venous Thromboembolism, Menstruation
RAMBLE - Rivaroxaban vs. Apixaban for Heavy Menstrual Bleeding
A large proportion of women with menstruating potential with newly diagnosed VTE or atrial fibrillation, treated with apixaban will have less menstrual blood loss than patients randomized to rivaroxaban.
- Trial name
- (RAMBLE) (NCT02829957)
- Testing
- Apixaban, Rivaroxaban
- Where
- 2 sites in United States
- Volunteers
- 19 people
- Sponsor
- Indiana University
Anticoagulation With Apixaban
Apixaban Validation Study - Additional Study on Fresh Samples
The objective is to demonstrate the performances of STA® - Apixaban Calibrator \& STA® - Apixaban Control used in combination with STA® - Liquid Anti-Xa to measure apixaban concentration in plasma.
- Trial name
- NCT03073265
- Testing
- STA-Apixaban Calibrator & Control
- Where
- 2 sites in United States
- Volunteers
- 109 people
- Sponsor
- Diagnostica Stago
Venous Thrombosis
Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism
The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatment for deep vein thrombosis…
- Trial name
- NCT00633893
- Testing
- Apixaban
- Where
- 428 sites in United States, Argentina and 27 more
- Volunteers
- 2,711 people
- Sponsor
- Bristol-Myers Squibb
COVID-19
Efficacy and Safety of Apixaban in COVID-19 Coagulopathy Patients With Respiratory Severity Under Critical Care
The purpose of the study is to describe the safety and efficacy outcomes of a cohort of ICU patients with severe COVID-19 respiratory disease treated with therapeutic dose Apixaban for COVID-19 at a tertiary public health care…
- Trial name
- ECRU (NCT05088928)
- Testing
- Apixaban, Rivaroxaban
- Where
- Pakistan
- Volunteers
- 40 people
- Sponsor
- Scotmann Pharmaceuticals
Spinal Cord Injuries, Spinal Diseases
Prevention of Thromboembolism Using Apixaban vs Enoxaparin Following Spinal Cord Injury
Currently, Enoxaparin is the usual prophylactic anticoagulant treatment at the acute and sub-acute phases of spinal cord injury (SCI).
- Trial name
- NCT05484557
- Testing
- Apixaban, Enoxaparin Sodium
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Loewenstein Hospital
Healthy Volunteers, Fasting
Comparative Bioavailability Study of TAH3311 5 mg Oral Dissolving Film vs ELIQUIS® 5 mg Tablet in Healthy Volunteers
The goal of this clinical trial is to evaluate the pharmacokinetic profiles and bioequivalence, and to determine the safety and tolerability of the TAH3311 Oral Dissolving Film (ODF) 5mg compared with ELIQUIS® (Apixaban) 5mg Oral…
- Conditions
- Healthy Volunteers, Fasting, Fed
- Trial name
- NCT05995119
- Testing
- Apixaban 5 mg Oral Dissolving Film (TAH3311) and Tablet (Eliquis®)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- TAHO Pharmaceuticals Ltd.
Gynecologic Cancer, Venous Thromboembolism
Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy
The study will evaluate the incidence of major bleeding (including clinically relevant non-major (CRNM) bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg twice a day (BID) compared to…
- Trial name
- NCT02366871
- Testing
- Oral apixaban, Subcutaneous enoxaparin
- Where
- 2 sites in United States
- Volunteers
- 400 people
- Sponsor
- University of Colorado, Denver
Treatment of Venous Thromboembolism in Cancer Patients, Venous Thromboembolism
An Observational Study Called H2H-OSCAR-US to Learn More About How Well Rivaroxaban Works and How Safe it is Compared to Apixaban Under Real World Conditions in People in the US With Cancer Who Have Problems Due to Formation of Blood Clots in the Veins (Venous Thromboembolism)
This is an observational study in which patient data from the past on venous thromboembolism (VTE) in people with cancer is studied. In observational studies, only observations are made without specified advice or interventions.
- Conditions
- Treatment of Venous Thromboembolism in Cancer Patients, Venous Thromboembolism, Cancer
- Trial name
- H2H-OSCAR-US (NCT05461807)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939), Apixaban
- Where
- Germany
- Volunteers
- 2,437 people
- Sponsor
- Bayer
Anti-Xa Activity
A Pilot Study Investigating Apixaban and Dexamethasone InterAction in Multiple Myeloma
This pilot study will investigate the impact of dexamethasone (DEX) on anti-Xa levels in participants taking apixaban 2.5 mg twice a day by mouth (PO BID).
- Trial name
- ADAM (NCT02749617)
- Testing
- apixaban
- Where
- Canada
- Volunteers
- 2 people
- Sponsor
- University of British Columbia
Neoplasms, Embolism
Anticoagulation in Patients With Venous Thromboembolism and Cancer
This study is a retrospective analysis of observational cohorts using data from prospectively collected administrative/claims data to investigate treatment patterns,healthcare resource utilisation (HCRU), direct and indirect…
- Trial name
- VICTORIE (NCT04618913)
- Testing
- Apixaban, Rivaroxaban, Edoxaban
- Where
- United Kingdom
- Volunteers
- 1 people
- Sponsor
- Pfizer